Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand.
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system. The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts. OPGL expression in T cells is induced by antigen receptor engagement, which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“RANKL is produced by numerous cell types including cells of the osteoblast lineage (46,47) and activated T cells (42,48,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“T Cells express both soluble and membrane-bound forms of RANKL (49,50), and both forms are implicated in focal bone erosions associated with inflammatory arthritis (26,49).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“Within the developed immune system, RANKL is expressed by T cells (42), RANK is expressed by dendritic cells (49), and OPG is expressed by B lymphocytes and dendritic cells (4,70).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“However, RANK and RANKL knockout mice had normal Peyer's patches and intact splenic architecture (49,62), indicating that the development of lymph nodes and secondary lymphoid organs can be differentially regulated.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
In the citing paper
“RANKL inhibition via recombinant OPG treatment also results in marked suppression of bone erosions and osteoclasts in several rodent models, including adjuvant arthritis (26,49,177,232,233), collagen-induced arthritis (26,181,233), and TNF-mediated arthritis (136, 234).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [49]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationOPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph node organogenesis.
Kong, Y.-Y., Yoshida, H., Sarosi, I., Tan, H.-L., Timms, E., Capparelli, C., Morony, S., Oliveira-dos-Santos, A. J., Van, G., Itie, A., et al. (1999) · Nature · doi:10.1038/16852 · Cited by 3,351 · cited 1×
“We show that: (1) p66 is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) or irradiation with ultraviolet light; (2) ablation of p66 enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serinephosphorylation defective mutant of p66 cannot restore the normal stress res…”
BackgroundSelf-citationRAG-1-deficient mice have no mature B and T lymphocytes
Mombaerts, P., Iacomini, J., Johnson, R. S., Herrup, K., Tonegawa, S., & Papaioannou, V. E. (1992) · Cell · doi:10.1016/0092-8674(92)90030-g · Cited by 2,931
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Self-citationROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS
Feldmann, M., Brennan, F. M., & Maini, R. N. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.397 · Cited by 2,514
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function.
Anderson, D. M., Maraskovsky, E., Billingsley, W. L., Dougall, W. C., Tometsko, M. E., Roux, E. R., Teepe, M. C., DuBose, R. F., Cosman, D., & Galibert, L. (1997) · Nature · doi:10.1038/36593 · Cited by 2,290
Kotake, S., Udagawa, N., Takahashi, N., Matsuzaki, K., Itoh, K., Ishiyama, S., Saito, S., Inoue, K., Kamatani, N., Gillespie, M. T., et al. (1999) · Journal of Clinical Investigation · doi:10.1172/jci5703 · Cited by 1,696
Hsu, H., Lacey, D. L., Dunstan, C. R., Solovyev, I., Colombero, A., Timms, E., Tan, H.-L., Elliott, G., Kelley, M. J., Sarosi, I., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.7.3540 · Cited by 1,636
Self-citationWong, B. R., Rho, J., Arron, J., Robinson, E., Orlinick, J., Chao, M., Kalachikov, S., Cayani, E., Bartlett, F. S., Frankel, W. N., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.40.25190 · Cited by 1,042
Cited by
Items 801–900 of 1,007
Durand, M., Boire, G., Komarova, S. V., Dixon, S. J., Sims, S. M., Harrison, R. E., Nabavi, N., Maria, O. M., Manolson, M. F., Mizianty, M. J., et al. (2010) · Bone · doi:10.1016/j.bone.2010.10.167 · Cited by 52
“OCs arise by fusion of these precursors in the presence of M-CSF and RANKL, two cytokines indispensable for osteoclastogenesis [7–12].”
BackgroundDetection and characterization of RANK ligand and osteoprotegerin in the thyroid gland
Hofbauer, L. C., Kluger, S., Kühne, C., Dunstan, C. R., Burchert, A., Schoppet, M., Zielke, A., & Heufelder, A. E. (2002) · Journal of Cellular Biochemistry · doi:10.1002/jcb.10242 · Cited by 50
Mature and activated osteoclasts exist in the synovium of rapidly destructive coxarthrosis
Ogawa, K., Mawatari, M., Komine, M., Shigematsu, M., Kitajima, M., Kukita, A., & Hotokebuchi, T. (2007) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-007-0761-0 · Cited by 46
“This major pathway can be inhibited by OPG [23,24].”
BackgroundInfluentialBisphosphonates: Environmental protection for the joint?
Goldring, S. R., & Gravallese, E. M. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20383 · Cited by 45
Cellular Interactions at Commercially Pure Titanium Implants
Cooper, L. F. (2003) · CRC Press eBooks · doi:10.1201/9780203491430.ch9 · Cited by 46
Apoptosis in rheumatoid arthritis: friend or foe
Liu, H., & Pope, R. M. (2004) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2004.04.010 · Cited by 49
Franchimont, N., Lambert, C., Huynen, P., Ribbens, C., Relic, B., Chariot, A., Bours, V., Piette, J., Merville, M., & Malaise, M. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20727 · Cited by 46
Wu, H., Khanna, D., Park, G. S. H., Gersuk, V. H., Nepom, G. T., Wong, W. K., Paulus, H. E., & Tsao, B. P. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20555 · Cited by 46
Immune System Acts on Orthodontic Tooth Movement: Cellular and Molecular Mechanisms
Gao, Y., Min, Q., Li, X., Liu, L., Lv, Y., Xu, W., Liu, X., & Wang, H. (2022) · BioMed Research International · doi:10.1155/2022/9668610 · Cited by 56
“It is also capable of secreting IFN-γ which polarize macrophages into M1 [40, 41] and releasing RANKL which induces osteoclasts di ff erentiation by binding to RANK [42, 43].”
Li, H., Lu, Y., Qian, J., Zheng, Y., Zhang, M., Bi, E., He, J., Liu, Z., Xu, J., Gao, J., et al. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2294 · Cited by 47
Kobbe, P., Kaczorowski, D. J., Yoram Vodovotz, B., Tzioupis, C. H., Mollen, K. P., Billiar, T. R., & Pape, H. (2008) · Shock · doi:10.1097/shk.0b013e31816f257e · Cited by 45
Systemic bone effects of biologic therapies in rheumatoid arthritis and ankylosing spondylitis
Confavreux, C. B., & Chapurlat, R. D. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1462-4 · Cited by 45
“Initially, in collagen-induced arthritis, the articular bone destruction was prevented by osteoprotegerin [45, 46].”
BackgroundFaienza, M. F., Brunetti, G., Colucci, S. C., Piacente, L., Ciccarelli, M., Giordani, L., Vecchio, G., D’Amore, M., Albanese, L., Cavallo, L., et al. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2446 · Cited by 50
Vibration enhances osteoclastogenesis by inducing RANKL expression via NF-κB signaling in osteocytes
Sakamoto, M., Fukunaga, T., Sasaki, K., Seiryu, M., Yoshizawa, M., Takeshita, N., & Takano‐Yamamoto, T. (2019) · Bone · doi:10.1016/j.bone.2019.03.024 · Cited by 53
Buckley, K. A., & Fraser, W. D. (2002) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1177/000456320203900602 · Cited by 56
Rutsch, F., & Terkeltaub, R. A. (2003) · Current Opinion in Rheumatology · doi:10.1097/00002281-200305000-00019 · Cited by 49
Serum measurement of osteoprotegerin--clinical relevance and potential applications
Hofbauer, L., & Schoppet, M. (2001) · European Journal of Endocrinology · doi:10.1530/eje.0.1450681 · Cited by 45
Matsuda, K., Shiba, N. N., & Hiraoka, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065173 · Cited by 54
“prevented by suppressing osteoclasts and RANKL expression [5,55].”
BackgroundDecreased bone formation and increased osteoclastogenesis cause bone loss in mucolipidosis II
Kollmann, K., Pestka, J. M., Kühn, S. C., Schöne, E., Schweizer, M., Karkmann, K., Otomo, T., Catalá-Lehnen, P., Failla, A. V., Marshall, R. P., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302979 · Cited by 50
“…that osteoblasts are critical regulators of osteoclastogenesis, there is increasing evidence that other cell types (such as lymphocytes, osteocytes or chondrocytes) are a signi fi cant source of Rankl thereby controlling bone resorption (Kong et al, 1999; Nakashima et al, 2011; Xiong et al, 2011).”
Efficacy of denosumab combined with bDMARDs on radiographic progression in rheumatoid arthritis
Hasegawa, T., Kaneko, Y., Izumi, K., & Takeuchi, T. (2016) · Joint Bone Spine · doi:10.1016/j.jbspin.2016.05.010 · Cited by 44
Novel Functions of RANK(L) Signaling in the Immune System
Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1050-9_9 · Cited by 53
Self-citationBone changes in early rheumatoid arthritis
Green, M. J., & Deodhar, A. A. (2001) · Best Practice & Research Clinical Rheumatology · doi:10.1053/berh.2000.0129 · Cited by 44
Yen, M., Tsai, H.-F., Wu, Y., Hwa, H., Lee, B.-H., & Hsu, P. (2008) · Molecular Immunology · doi:10.1016/j.molimm.2007.12.003 · Cited by 48
Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG)
Hofbauer, L. C. (2006) · Annales d Endocrinologie · doi:10.1016/s0003-4266(06)72569-0 · Cited by 47
Suematsu, A., Tajiri, Y., Nakashima, T., Taka, J., Ochi, S., Oda, H., Nakamura, K., Tanaka, S., & Takayanagi, H. (2007) · Modern Rheumatology · doi:10.1007/s10165-006-0531-1 · Cited by 45
Influence of RANKL inhibition on immune system in the treatment of bone diseases
Fouque-Aubert, A., & Chapurlat, R. D. (2007) · Joint Bone Spine · doi:10.1016/j.jbspin.2007.05.004 · Cited by 49
Reproductive toxicity of denosumab in cynomolgus monkeys
Bussiere, J. L., Pyrah, I. T. G., Boyce, R. W., Branstetter, D., Loomis, M., Andrews-Cleavenger, D., Farman, C. A., Elliott, G. S., & Chellman, G. J. (2013) · Reproductive Toxicology · doi:10.1016/j.reprotox.2013.07.018 · Cited by 45
Physiology and pathophysiology of the RANKL/RANK system
Hanada, R., Hanada, T., & Penninger, J. M. (2010) · Biological Chemistry · doi:10.1515/bc.2010.149 · Cited by 46
Self-citationShashkova, E. V., Trivedi, J., Cline-Smith, A., Ferris, C., Buchwald, Z. S., Gibbs, J., Novack, D. V., & Aurora, R. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600253 · Cited by 45
Narisawa, M., Kubo, S., Okada, Y., Yamagata, K., Nakayamada, S., Sakata, K., Yamaoka, K., & Tanaka, Y. (2020) · Bone · doi:10.1016/j.bone.2020.115616 · Cited by 43
RANK, RANKL and OPG in inflammatory arthritis and periprosthetic osteolysis.
Ritchlin, C. T., Schwarz, E. M., O’Keefe, R. J., & Looney, R. J. (2004) · PubMed · Cited by 42
Receptor activator of nuclear factor κB ligand (RANKL): another link between breast and bone
Martin, T. J., & Gillespie, M. T. (2001) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00351-9 · Cited by 49
OX40L blockade is therapeutic in arthritis, despite promoting osteoclastogenesis
Findlay, E. G., Danks, L., Madden, J., Cavanagh, M., McNamee, K., McCann, F. E., Snelgrove, R. J., Shaw, S., Feldmann, M., Taylor, P. C., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1321071111 · Cited by 46
Toh, K., Kukita, T., Wu, Z., Kukita, A., Sandra, F., Tang, Q. Y., Nomiyama, H., & Iijima, T. (2004) · Laboratory Investigation · doi:10.1038/labinvest.3700132 · Cited by 43
Ohishi, M., Matsumura, Y., Aki, D., Mashima, R., Taniguchi, K., Kobayashi, T., Kukita, T., Iwamoto, Y., & Yoshimura, A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.5.3024 · Cited by 43
Lories, R. J. U., & Luyten, F. P. (2001) · Clinical Rheumatology · doi:10.1007/s100670170095 · Cited by 48
Okamoto, K., & Takayanagi, H. (2023) · Bone · doi:10.1016/j.bone.2023.116675 · Cited by 42
Ivanovska, N., & Dimitrova, P. A. (2011) · Arthritis Research & Therapy · doi:10.1186/ar3283 · Cited by 44
Chen, C.-H., Chen, H.-A., Liao, H., Liu, C., Tsai, C., & Chou, C. (2010) · Clinical Rheumatology · doi:10.1007/s10067-010-1543-y · Cited by 42
The hidden secrets of soluble RANKL in bone biology
Elango, J., Bao, B., & Wu, W. (2021) · Cytokine · doi:10.1016/j.cyto.2021.155559 · Cited by 50
Vattakuzhi, Y., Abraham, S., Freidin, A. J., Clark, A. R., & Horwood, N. J. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34403 · Cited by 49
Bovine lactoferrin improves bone status of ovariectomized mice via immune function modulation
Malet, A., Bournaud, E., Lan, A., Mikogami, T., Tomé, D., & Blais, A. (2011) · Bone · doi:10.1016/j.bone.2011.02.002 · Cited by 49
“T cell activation increases osteoclastic cytokines such as the receptor activator of NFκB ligand (RANKL) and pro-inflammatory cytokines which enhance osteoclast differentiation, maturation, activation, lifespan and modulate the immune system in rodents and humans [15,22,23].”
BackgroundSato, T., Watanabe, K., Masuhara, M., Hada, N., & Hakeda, Y. (2006) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-006-0723-y · Cited by 41
Liver-derived IGF-I is permissive for ovariectomy-induced trabecular bone loss
Lindberg, M. K., Svensson, J., Venken, K., Chavoshi, T. M., Andersson, N., Skrtic, S., Isaksson, O. G. P., Vanderschueren, D., Carlsten, H., & Ohlsson, C. (2005) · Bone · doi:10.1016/j.bone.2005.07.027 · Cited by 44
Jules, J., Shi, Z., Liu, J., Xu, D., Wang, S., & Feng, X. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.149484 · Cited by 45
Spelling, P. F., Bonfá, E., Caparbo, V. F., & Pereira, R. M. R. (2008) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740802116224 · Cited by 46
Therapeutic implications of osteoprotegerin
Fili, S., Karalaki, M., & Schaller, B. J. (2009) · Cancer Cell International · doi:10.1186/1475-2867-9-26 · Cited by 48
Denosumab for bone diseases: translating bone biology into targeted therapy
Tsourdi, E. A., Rachner, T. D., Rauner, M., Hamann, C., & Hofbauer, L. C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0454 · Cited by 45
Does systemic inflammation and immune activation contribute to fracture risk in HIV?
McGinty, T., Mirmonsef, P., Mallon, P. W. G., & LANDAY, A. L. (2016) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000275 · Cited by 45
Molecular Mechanisms Leading from Periodontal Disease to Cancer
Sobocki, B. K., Basset, C. A., Bruhn-Olszewska, B., Olszewski, P., Szot, O., Kaźmierczak-Siedlecka, K., Guziak, M., Nibali, L., & Leone, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020970 · Cited by 47
Saidenberg-Kermanac’h, N., Bessis, N., Lemeiter, D., de Vernejoul, M. C., Boissier, M., & Cohen-Solal, M. E. (2004) · Journal of Clinical Immunology · doi:10.1023/b:joci.0000029116.12371.bf · Cited by 46
Osteoclasts, mononuclear phagocytes, and c-Fos: new insight into osteoimmunology
Matsuo, K., & Ray, N. (2004) · The Keio Journal of Medicine · doi:10.2302/kjm.53.78 · Cited by 47
Ledesma-Colunga, M. G., Adán, N., Ortiz, G., Solís-Gutiérrez, M., López-Barrera, F., Martínez de la Escalera, G., & Clapp, C. (2017) · Arthritis Research & Therapy · doi:10.1186/s13075-017-1290-4 · Cited by 40
“Tnfrsf11b encodes for OPG, a soluble decoy receptor that neutralizes RANKL and prevents bone erosion in AIA [4].”
BackgroundOsteoimmunology and Its Implications for Transplantation
Pacifici, R. (2013) · American Journal of Transplantation · doi:10.1111/ajt.12380 · Cited by 40
Estrogen receptor-α expression in neuronal cells affects bone mass
Ohlsson, C., Engdahl, C., Börjesson, A. E., Windahl, S. H., Studer, E., Westberg, L., Eriksson, E., Koskela, A., Tuukkanen, J., Krust, A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1111436109 · Cited by 40
Mechanisms of tissue damage in arthritis
Blüml, S., Redlich, K., & Smolen, J. S. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0442-8 · Cited by 43
“In addition, Tcells, especially Th17, but also Th1 Tcells, express RANKL, which has been shown to drive local osteoclastogenesis [54, 55].”
BackgroundSmith, H. S., & Barkin, R. L. (2013) · American Journal of Therapeutics · doi:10.1097/mjt.0b013e3182456dff · Cited by 44
Bacterial modulators of bone remodeling in the periodontal pocket
Henderson, B. E., & Kaiser, F. (2017) · Periodontology 2000 · doi:10.1111/prd.12160 · Cited by 44
Selective Costimulation Modulators: A Novel Approach for the Treatment of Rheumatoid Arthritis
Kremer, J. M. (2005) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000166626.68898.17 · Cited by 40
Yamaura, K., Yonekawa, T., Nakamura, T., Yano, S., & Ueno, K. (2003) · Journal of Pharmacological Sciences · doi:10.1254/jphs.92.43 · Cited by 40
The emerging field of osteoimmunology
Mensah, K. A., Li, J., & Schwarz, E. M. (2009) · Immunologic Research · doi:10.1007/s12026-009-8093-x · Cited by 43
Self-citationSakurai, A., Okahashi, N., Nakagawa, I., Kawabata, S., Amano, A., Ooshima, T., & Hamada, S. (2003) · Infection and Immunity · doi:10.1128/iai.71.10.6019-6026.2003 · Cited by 43
Teng, Y.-T. A. (2002) · Infection and Immunity · doi:10.1128/iai.70.9.5269-5273.2002 · Cited by 40
Pfeil, A., Haugeberg, G., Hansch, A., Renz, D. M., Lehmann, G., Malich, A., Wolf, G., & Böttcher, J. (2011) · Arthritis Care & Research · doi:10.1002/acr.20423 · Cited by 42
Titanji, K., Vunnava, A., Foster, A., Sheth, A. N., Lennox, J. L., Knežević, A., Shenvi, N. V., Easley, K. A., Ofotokun, I., & Weitzmann, M. N. (2018) · AIDS · doi:10.1097/qad.0000000000001764 · Cited by 38
“bone loss, including rheumatoid arthritis (RA)[11], postmenopausal osteoporosis[12] and periodontal infection[7, 13].”
BackgroundResultInfluentialMicroRNA‐21 promotes orthodontic tooth movement by modulating the RANKL/OPG balance in T cells
Wu, L., Su, Y., Lin, F., Zhu, S., Wang, J., Hou, Y., Du, J., Liu, Y. F., & Guo, L. (2019) · Oral Diseases · doi:10.1111/odi.13239 · Cited by 39
Cheng, M., Tan, B., Wu, X., Liao, F., Wang, F., & Huang, Z. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.636231 · Cited by 36
Molecular mechanisms of triggering, amplifying and targeting RANK signaling in osteoclasts
Kuroda, Y., & Matsuo, K. (2012) · World Journal of Orthopedics · doi:10.5312/wjo.v3.i11.167 · Cited by 45
T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion
O’Gradaigh, D., & Compston, J. E. (2003) · Rheumatology · doi:10.1093/rheumatology/keg447 · Cited by 38
Microbiota-bone axis in ageing-related bone diseases
Fu, L., Zhang, P., Wang, Y., & Liu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1414350 · Cited by 44
RANK(L) as a Key Target for Controlling Bone Loss
Leibbrandt, A., & Penninger, J. M. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-89520-8_9 · Cited by 39
Self-citationHIV infection and osteoporosis
Compston, J. E. (2015) · BoneKEy Reports · doi:10.1038/bonekey.2015.3 · Cited by 41
“Chronic immune reconstitution may also have a role in bone loss associated with ART initiation, as a result of increased circulating levels of proinflammatory, proresorptive cytokines.(34,35) Interestingly, there is emerging evidence that adverse effects on bone may be reduced or absent with one class of ART drugs: th…”
BackgroundNa, M., Jarneborn, A., Ali, A. M., Welin, A., Magnusson, M., Stokowska, A., Pekna, M., & Jin, T. (2016) · Infection and Immunity · doi:10.1128/iai.01520-15 · Cited by 39
Kichev, A., Eede, P., Gressèns, P., Thornton, C., & Hagberg, H. (2017) · Developmental Neuroscience · doi:10.1159/000464244 · Cited by 41
Bone Structure, Development and Bone Biology
Khurana, J. S., & Safadi, F. F. (2009) · Springer eBooks · doi:10.1007/978-0-387-89845-2_1 · Cited by 45
Localization of RANKL in osteolytic tissue around a loosened joint prosthesis
堀木, 充., Nakase, T., Myoui, A., Sugano, N., Nishii, T., Tomita, T., Miyaji, T., & Yoshikawa, H. (2004) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-003-0493-8 · Cited by 38
“Recently, a potent molecule responsible for osteoclastogenesis, has been identified as a ligand for receptor activation of nuclear factor (NF)-kB (RANKL) [7–9].”
BackgroundIchimiya, H., Takahashi, T., Ariyoshi, W., Takano, H., Matayoshi, T., & Nishihara, T. (2006) · Oral Surgery Oral Medicine Oral Pathology Oral Radiology and Endodontology · doi:10.1016/j.tripleo.2006.05.026 · Cited by 38
Beyond Self and Nonself: Fuzzy Recognition of the Immune System
Leng, Q., & Bentwich, Z. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2002.01105.x · Cited by 41
Immunoregulation of bone remodelling
Singh, A. K., Mehdi, A., Srivastava, R., & Verma, N. (2012) · International Journal of Critical Illness and Injury Science · doi:10.4103/2229-5151.97271 · Cited by 49
Ju, J., Cho, M., Jhun, J.-Y., Park, M.-J., Oh, H.-J., Min, S., Cho, Y. G., Hwang, S.-Y., Kwok, S., Seo, S. H., et al. (2007) · Immunology Letters · doi:10.1016/j.imlet.2007.09.011 · Cited by 38
IBD and Skeletal Health: Children Are Not Small Adults!
Sylvester, F. A. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000188341.96726.15 · Cited by 38
Mensah, K. A., Mathian, A., Ma, L., Xing, L., Ritchlin, C. T., & Schwarz, E. M. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27312 · Cited by 40
Agarwal, S., Misra, R., & Aggarwal, A. (2008) · Rheumatology International · doi:10.1007/s00296-008-0805-3 · Cited by 37
Osteoclast Differentiation Factor in Human Osteosarcoma Cell Line
Kinpara, K., Mogi, M., Kuzushima, M., & Togari, A. (2000) · Journal of Immunoassay · doi:10.1080/01971520009349540 · Cited by 38
Prostate carcinoma cells that have resided in bone have an upregulated IGF‐I axis
Rubin, J. E., Chung, L. W. K., Fan, X., Zhu, L., Murphy, T. C., Nanes, M. S., & Rosen, C. J. (2003) · The Prostate · doi:10.1002/pros.10299 · Cited by 38
Bone and Mineral Metabolism in Human Immunodeficiency Virus Infection
Kühne, C., Heufelder, A. E., & Hofbauer, L. C. (2001) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.2001.16.1.2 · Cited by 38
“(14,16) Moreover, IL-1 and TNFa are capable of directly inducing differentiation and activation of osteoclasts in the absence of RANKL.”
BackgroundCellular and molecular interactions between immune system and bone.
Grčević, D., Katavić, V., Lukić, I. K., Kovačić, N., Lorenzo, J. A., & Marušić, A. (2001) · PubMed · Cited by 42
Mechanisms of osteoclast activation in inflammatory bone loss in rheumatoid arthritis
Rauner, M., & Bözec, A. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-025-01323-9 · Cited by 52
“Preclinical and clinical studies have shown the efficacy of blocking RANKL to halt inflammation-induced bone loss and bone erosions, without affecting the course of inflammation, which we discuss later in this Review 34,55–57 .”
InfluentialHoy, J., Grund, B., Roediger, M. P., Ensrud, K. E., Brar, I., Colebunders, R., Castro, N. D., Johnson, M. A., Sharma, A., Carr, A., et al. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1861 · Cited by 37
Onal, M., John, H. C. S., Danielson, A. L., & Pike, J. W. (2015) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2698 · Cited by 40
Altered bone remodeling in psoriatic arthritis
Mensah, K. A., Schwarz, E. M., & Ritchlin, C. T. (2008) · Current Rheumatology Reports · doi:10.1007/s11926-008-0050-5 · Cited by 43
Lymphocyte-derived cytokines in inflammatory arthritis
Horwood, N. J. (2008) · Autoimmunity · doi:10.1080/08916930701694766 · Cited by 36
Effects of activated T cells on osteoclastogenesis depend on how they are activated
Wyzga, N., Varghese, S., Wikel, S. K., CANALIS, E. M., & Sylvester, F. A. (2004) · Bone · doi:10.1016/j.bone.2004.04.022 · Cited by 37
“The wells were then washed with phosphate-buffered saline (PBS) and T lymphocytes were added at a concentration of 10/ well in 1 ml of RPMI 1640 culture medium with 10% FBS containing anti-CD28 (200 ng/ml) antibody [6]; (2) Concanavalin A (Con A) at 5 Ag/ml (Sigma) [12]; (3) Phytohemagglutinin (PHA) at 5 Ag/ml (Sigma)…”
BackgroundMethodInfluentialLange, U., Dischereit, G., Tarner, I. H., Frommer, K., Neumann, E., Müller‐Ladner, U., & Kürten, B. (2016) · Clinical Rheumatology · doi:10.1007/s10067-016-3236-7 · Cited by 37
Increase in RANKL: OPG Ratio in Synovia of Patients with Temporomandibular Joint Disorder
Wakita, T., Mogi, M., Kurita, K., Kuzushima, M., & Togari, A. (2006) · Journal of Dental Research · doi:10.1177/154405910608500709 · Cited by 40
Seo, S. W., Lee, D., Minematsu, H., Kim, A. D., Shin, M., Cho, S. K.-W., Kim, D. W., Yang, J., & Lee, F. Y. (2009) · Bone · doi:10.1016/j.bone.2009.10.032 · Cited by 37
The deficiency of immunoregulatory receptor PD-1 causes mild osteopetrosis
Nagahama, K., Aoki, K., Nonaka, K., Saito, H., Takahashi, M., Varghese, B. J., Shimokawa, H., Azuma, M., Ohya, K., & Ohyama, K. (2004) · Bone · doi:10.1016/j.bone.2004.06.018 · Cited by 40
“CTLA-4-deficient mice (CTLA-4 / mice) show severe osteopenia with an increase in osteoclast number [6].”
BackgroundInfluentialRANKL inhibition for the management of patients with benign metabolic bone disorders
Anastasilakis, A. D., Toulis, K. A., Pοlyzos, S. A., & Terpos, E. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903048929 · Cited by 38
“Within the developed immune system, RANKL is expressed by T cells [13], RANK is expressed by dendritic cells [14], and OPG is expressed by B-lymphocytes and dendritic cells [9,15].”
BackgroundRegulation of RANKL by biomechanical loading in fibrochondrocytes of meniscus
Deschner, J., Wypasek, E., Ferretti, M., Rath, B., Anghelina, M. I., & Agarwal, S. (2005) · Journal of Biomechanics · doi:10.1016/j.jbiomech.2005.05.034 · Cited by 42
Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells
Okada, T., Akikusa, S., Okuno, H., & Kodaka, M. (2003) · Clinical & Experimental Metastasis · doi:10.1023/a:1027362507683 · Cited by 40
Metadata
- Authors
- Kong, Y.-Y., Feige, U., Sarosi, I., Bolon, B., Tafuri, A., Morony, S., Capparelli, C., Li, J., Elliott, R., McCabe, S., Wong, T., Campagnuolo, G., Moran, E., Bogoch, E. R., Van, G., Nguyen, L. T., Ohashi, P. S., Lacey, D. L., Fish, E., Boyle, W. J., & Penninger, J. M.
- Affiliations
- Amgen (Canada) (CA)
- Amgen (United States) (US)
- St. Michael's Hospital (CA)
- University of Toronto (CA)
- ORCID
- Venue
- Nature
- Published
- 1999-11
- Volume
- 402
- Issue
- 6759
- Pages
- 304-309
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1677043489
- Cited by
- 1,856
- References
- 24
- Citations by year
- 2026: 17 · 2025: 33 · 2024: 36 · 2023: 33 · 2022: 25 · 2021: 36 · 2020: 47 · 2019: 43 · 2018: 38 · 2017: 59 · 2016: 64 · 2015: 82 · 2014: 80 · 2013: 85 · 2012: 77
- FWCI
- 26.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Cystic Fibrosis Foundation
- U.S. Public Health Service
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
- Health Sciences › Medicine › Rheumatology › Osteomyelitis and Bone Disorders Research
- Keywords
- osteoprotegerin ligand, osteoprotegerin, RANK, activated T cells, adjuvant-induced arthritis, bone loss, osteoclastogenesis, joint destruction, cartilage destruction, T cell activation, bone remodeling, osteoclasts
- MeSH terms
- Animals, Arthritis, Experimental, Bone and Bones, Bone Resorption, Carrier Proteins, Cartilage, Cells, Cultured, Glycoproteins, Humans, Lymphocyte Activation, Membrane Glycoproteins, Mice, Inbred C57BL, Rats, Inbred Lew, T-Lymphocytes, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Coculture Techniques, Mice, Rats, Osteoprotegerin, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.